BYK204165

Modify Date: 2024-01-15 22:49:34

BYK204165 Structure
BYK204165 structure
Common Name BYK204165
CAS Number 1104546-89-5 Molecular Weight 252.26800
Density N/A Boiling Point N/A
Molecular Formula C15H12N2O2 Melting Point N/A
MSDS USA Flash Point N/A
Symbol GHS07
GHS07
Signal Word Warning

 Use of BYK204165


BYK204165 is a potent PARP inhibitor. BYK204165 inhibits cell-free recombinant human PARP-1 (hPARP-1) with a pIC50 of 7.35 (pKi=7.05), and murine PARP-2 (mPARP-2) with a pIC50 of 5.38, respectively. BYK204165 displays 100-fold selectivity for PARP-1[1].

 Names

Name (4Z)-4-[(1-Methyl-1H-pyrrol-2-yl)methylene]-1,3(2H,4H)-isoquinoli nedione
Synonym More Synonyms

 BYK204165 Biological Activity

Description BYK204165 is a potent PARP inhibitor. BYK204165 inhibits cell-free recombinant human PARP-1 (hPARP-1) with a pIC50 of 7.35 (pKi=7.05), and murine PARP-2 (mPARP-2) with a pIC50 of 5.38, respectively. BYK204165 displays 100-fold selectivity for PARP-1[1].
Related Catalog
Target

hPARP-1:7.35 (pIC50)

mPARP-2:5.38 (pIC50)

In Vitro In kinetic experiments with human PARP-1, BYK204165 exhibits potent and competitive inhibition of enzyme activity, yielding a pKi value of 7.05[1]. BYK204165 exhibits low potency of PARP inhibition in C4I cells (pIC50 of 5.75)[1].
In Vivo BYK204165 is not investigated in vivo because of its short half-time (t1/2) of 23 min measured at rat microsomes in vitro[1].
References

[1]. Eltze T, et al. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Mol Pharmacol. 2008 Dec;74(6):1587-98.

 Chemical & Physical Properties

Molecular Formula C15H12N2O2
Molecular Weight 252.26800
Exact Mass 252.09000
PSA 54.59000
LogP 1.84610

 Safety Information

Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H317
Precautionary Statements P280
Hazard Codes Xi
RIDADR NONH for all modes of transport

 Articles1

More Articles
Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma.

Mol. Cancer Res. 13(3) , 470-82, (2015)

In neuroblastoma, MYCN genomic amplification and segmental chromosomal alterations including 1p or 11q loss of heterozygocity and/or 17q gain are associated with progression and poor clinical outcome....

 Synonyms

4-(1-methyl-1H-pyrrol-2-ylmethylene)-4H-isoquinolin-1,3-dione